Improved sleep parallels improvements in atopic dermatitis signs, symptoms, and quality of life in adult patients treated with dupilumab: 24-week results from the DUPISTAD study - 20/11/24
Doi : 10.1016/j.jaad.2024.05.100
Joseph F. Merola, MD a, ⁎ 
, Albert S. Chiou, MD b, Emmanuel During, MD c, d, Peter Foley, MD e, f, g, Jiangming Wu, PhD h, Marius Ardeleanu, MD i, Zafer E. Ozturk, MD j
, Albert S. Chiou, MD b, Emmanuel During, MD c, d, Peter Foley, MD e, f, g, Jiangming Wu, PhD h, Marius Ardeleanu, MD i, Zafer E. Ozturk, MD j a Department of Dermatology, Medicine and Rheumatology, UT Southwestern Medical Center, Dallas, Texas
b Department of Dermatology, Stanford University, Palo Alto, California
c Department of Neurology and Neurological Sciences, Stanford University, Palo Alto, California
d Division of Sleep Medicine, Department of Psychiatry and Behavioral Sciences, Stanford University, Palo Alto, California
e Skin Health Institute, Carlton, Victoria, Australia
f Department of Dermatology, St Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia
g Department of Medicine, The University of Melbourne, Parkville, Victoria, Australia
h Sanofi, Bridgewater, New Jersey
i Regeneron Pharmaceuticals Inc., Tarrytown, New York
j Sanofi, Cambridge, Massachusetts
∗Correspondence to: Joseph F. Merola, MD, Department of Dermatology, Medicine and Rheumatology, UT Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390Department of Dermatology, Medicine and RheumatologyUT Southwestern Medical Center5323 Harry Hines BoulevardDallasTX75390
Key words : atopic dermatitis, dupilumab, pruritus/itch, quality of life, sleep
Mappa
| Funding sources: This study was supported by Sanofi and Regeneron Pharmaceuticals Inc. Medical writing and editorial assistance were provided by Liselotte Delden of Excerpta Medica and funded by Sanofi and Regeneron Pharmaceuticals Inc., according to the Good Publication Practice guidelines. |
|
| IRB approval status: The study was conducted in accordance with the Declaration of Helsinki, the International Conference on Harmonization Good Clinical Practice guidelines, and applicable regulatory requirements. An independent data and safety monitoring committee conducted blinded monitoring of patient safety data. The local institutional review board or ethics committee at each study center oversaw trial conduct and documentation. All patients or their parents/guardians provided written informed consent before participating in the trial. |
© 2024
American Academy of Dermatology, Inc.. Pubblicato da Elsevier Masson SAS. Tutti i diritti riservati.
Vol 91 - N° 6
P. 1199-1201 - dicembre 2024 Ritorno al numero
Articolo precedente
- Integrating skin color assessments into clinical practice and research: A review of current approaches
- Valerie M. Harvey, Andrew Alexis, Chidubem A.V. Okeke, Lynn McKinley-Grant, Susan C. Taylor, Seemal R. Desai, Tarannum Jaleel, Candrice R. Heath, Sewon Kang, Neelam Vashi, Jenna Lester, Rebecca Vasquez, Michelle Rodrigues, Nada Elbuluk, Iltefat Hamzavi, Shawn G. Kwatra, Hema Sundaram, Caryn Cobb, Stafford G. Brown, Indermeet Kohli, Valerie D. Callender
- Evaluation of private and Medicaid insurance coverage for port-wine stain treatment with pulsed dye laser
- Sophia Ly, Priya Manjaly, Lisa Y. Shen
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?